Is it appropriate to initiate lisdexamfetamine (Vyvanse) for a patient with Attention‑Deficit/Hyperactivity Disorder, binge‑eating disorder, depression and hypomania who is already taking fluoxetine and quetiapine (Seroquel)?

Initiating Vyvanse in a Patient with Hypomania, Binge Eating Disorder, Depression, and ADHD on Fluoxetine and Quetiapine

Primary Recommendation

You should initiate lisdexamfetamine (Vyvanse) for this patient, as it is FDA-approved for both ADHD and moderate-to-severe binge eating disorder, and mood stabilization with quetiapine must be maintained concurrently to prevent manic destabilization. 1, 2

---

Treatment Algorithm Based on Symptom Hierarchy

Step 1: Confirm Mood Stabilization Before Stimulant Initiation

• Mood stabilizers must be established and optimized before introducing stimulant medications in patients with ADHD and comorbid mood disorders to minimize the risk of manic episodes. 3
• Your patient is already on quetiapine with improvement in mania and depression—this satisfies the prerequisite for safe stimulant initiation. 3
• Never initiate stimulant therapy in patients with unstable bipolar disorder or active manic/hypomanic symptoms, as stimulants can precipitate or worsen mood episodes. 3
• The standard of care is mood stabilizer plus stimulant, not stimulant monotherapy, for patients with confirmed bipolar spectrum disorders. 3

Step 2: Select Vyvanse as the Optimal Agent

• Lisdexamfetamine is the only FDA-approved medication for both ADHD and moderate-to-severe binge eating disorder in adults, making it uniquely suited to address two of this patient's three remaining symptoms. 1, 2, 4
• Vyvanse 50–70 mg/day demonstrated significantly greater reduction in binge eating days per week compared to placebo in pivotal trials, with marked reduction in relapse risk over 52 weeks. 2
• Vyvanse is a prodrug requiring enzymatic hydrolysis in red blood cells to convert to active d-amphetamine, which provides lower abuse potential compared to immediate-release stimulants—an important consideration given the impulsivity associated with binge eating disorder. 5, 6
• The prodrug mechanism provides consistent plasma concentrations throughout the day with duration of action extending 13–14 hours, eliminating the need for multiple daily doses. 6

Step 3: Dosing Protocol

• Start lisdexamfetamine at 30 mg once daily in the morning (the FDA-recommended starting dose for both ADHD and binge eating disorder). 1
• Titrate in increments of 10–20 mg at approximately weekly intervals based on ADHD symptom response and binge eating frequency. 1
• Target dose is 50–70 mg daily for optimal treatment of both ADHD and binge eating disorder; maximum dose is 70 mg daily. 1, 2
• Administer in the morning with or without food; avoid afternoon doses due to insomnia risk. 1

Step 4: Critical Monitoring Parameters

• Blood pressure and pulse at baseline and each titration visit—stimulants cause statistically significant cardiovascular effects. 3
• Weekly ADHD symptom ratings during titration using standardized scales (e.g., Adult ADHD Self-Report Scale). 3
• Binge eating frequency—track days per week with binge episodes as the primary outcome measure. 2
• Mood symptoms—systematically assess for emergence of hypomania, irritability, or agitation at every visit, as stimulants can destabilize mood in bipolar patients. 7, 3
• Sleep quality and appetite changes—common adverse effects that require counseling and management. 1
• Weight and height (baseline and periodic monitoring). 3

---

Safety Considerations and Drug Interactions

Fluoxetine + Vyvanse Combination

• There are no clinically significant pharmacokinetic drug-drug interactions between SSRIs and stimulants; this combination is well-established and safe. 3
• SSRIs do not alter the metabolism or clearance of dexamphetamine, supporting concurrent use when ADHD coexists with mood disorders. 3
• However, monitor for serotonin syndrome when combining serotonergic agents, though risk is low with this specific combination. 1

Quetiapine Continuation is Mandatory

• Continue quetiapine throughout Vyvanse treatment—discontinuing the mood stabilizer while adding a stimulant risks psychiatric decompensation. 3
• A randomized controlled trial demonstrated that low-dose mixed amphetamine salts were safe and effective for comorbid ADHD only after mood symptoms were stabilized with mood stabilizers. 3

Absolute Contraindications to Verify

• MAO inhibitors within 14 days (contraindicated due to hypertensive crisis risk). 3, 1
• Active psychosis or uncontrolled mania (your patient does not meet this criterion given quetiapine response). 3
• Symptomatic cardiovascular disease or uncontrolled hypertension. 1

---

Expected Outcomes and Timeline

ADHD Response

• Stimulants work within days, allowing rapid assessment of ADHD symptom response. 3
• 70–80% response rate when properly titrated to therapeutic doses. 3

Binge Eating Disorder Response

• Significant reduction in binge eating days per week typically observed within 12 weeks at target doses of 50–70 mg. 2
• Marked reduction in relapse risk demonstrated in long-term studies extending to 52 weeks. 2

Mood Stability

• Functional impairment from untreated ADHD persists despite improvement in mood symptoms, indicating that addressing ADHD directly is necessary to restore full functioning. 3
• Some patients with secondary depression show improvement once ADHD symptoms are treated, potentially reducing depressive symptoms indirectly. 3

---

Common Pitfalls to Avoid

• Do not assume a single antidepressant will effectively treat both ADHD and depression—no single antidepressant is proven for this dual purpose. 3
• Do not initiate Vyvanse if mood symptoms are not adequately controlled—unstable bipolar disorder is a contraindication to stimulant therapy. 3
• Do not discontinue quetiapine when starting Vyvanse—concurrent mood stabilization is mandatory. 3
• Do not underdose Vyvanse for binge eating disorder—target 50–70 mg daily for optimal efficacy in BED, not just ADHD symptom control. 1, 2
• Do not ignore the 13–14 hour duration of action—evening insomnia is a predictable adverse effect requiring morning-only dosing. 6

---

Tolerability Profile

• Most treatment-emergent adverse events are mild to moderate in intensity and transient. [2, 6
• Most common adverse events: dry mouth, headache, insomnia, decreased appetite, irritability. [1, 2
• Adverse events infrequently lead to discontinuation (6% in adult ADHD trials, similar in BED trials). [1, 2
• The tolerability profile in BED patients is similar to that observed in ADHD patients. 2

---

Why Vyvanse Over Other Stimulants

• Vyvanse is the only stimulant with FDA approval for binge eating disorder, making it the evidence-based choice for dual ADHD/BED treatment. [1, 2
• Lower abuse potential due to prodrug mechanism—therapeutically inactive until enzymatically converted in blood. [5, 6
• Once-daily dosing improves adherence and eliminates compliance issues with multiple daily doses. 6
• Consistent plasma concentrations throughout the day without the peaks and troughs of immediate-release formulations. 6